|Description||Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.|
|DrugBank||Primary Accession Number: DB00910|
|Type||Approved, Investigational, Small Molecule|
|Indication||For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4|
|Mechanism of Action||Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol`s biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.|
You need to load/activate the cURL extension (http://www.php.net/cURL).
|Protein Binding||99.8% (bound to plasma proteins)|